Page 21«..10..20212223..3040..»

Will bone marrow stem cells help heart attack patients …

By Sykes24Tracey

> My last post introduced the large-scale publicly funded clinical trial called BAMI (the effect of intracoronary reinfusion of Bone marrow-derived mononuclear cells on all course mortality in Acute Myocardial Infarction). That post focused on the role of the public purse in funding such trials and concluded that public monies have a major role to play in what companies would consider not fundable.

Since clinical trials are enormously expensive, however, it makes the choice of trial to run/fund incredibly difficult and important. The BAMI trial proposes to take whole bone marrow cells from patients who have had a heart attack and transplant them into the hearts of the patients with the hope that these cells will prevent people from re-hospitalization and/or death. Interestingly, the BAMI trial is billed as a stem cell therapy, when in reality it is a hodge-podge of un-fractionated cells that are injected into the heart. Cell therapy, yes. Stem cells, maybe not

When we hear about stem cell trials, we often think of permanent cures where the stem cell population(s) replaces damaged stem cells and operates as normal (e.g., as in the case of successful bone marrow transplantations where donor cells repopulate the recipient forever). I dont think it is likely that the cells in the BAMI trial will be setting up shop in the hearts of patients but one never knows and it would be very interesting to see if cells are still present at the two year endpoint. Present or not, if these cell suspensions achieve the 25% reduction in mortality and 15% reduction in re-hospitalization, then it may be worth it despite the lack of permanence.

Even for someone who has trained in the stem cells and regenerative medicine field for 10 years now, it is difficult to imagine how this (stem) cell therapy might work and what the underlying mechanism of action would be. If anything, I think the benefit would come from the other bone marrow cells injected (the non-stem cells) as a sort of directed delivery of key regenerative molecules or cells (e.g., cytokines, immune cells). These molecules may support tissue healing, they may prevent further damage, they may inhibit scarring, but realistically, we simply do not know what they will do and its a bit of a cowboy experiment when the data from previous trials are not exactly a ringing endorsement of promised success.

The only trial I could find, that had any indication of modest effects, was the TAC-HFTtrial (clinicaltrials.gov identifier NCT00768066) showing that the 1-year incidence of serious adverse events was 31.6% for mesenchymal stem cells, 31.6% for bone marrow cells, and 38.1% for placebo controls. This is a marginal decrease in adverse effects, and the trial only enrolled 65 patients.

On the other hand, the majority of completed studies lack strong positive data (as was also highlighted this Nature News article last week) including:

Despite these suggestions that this therapy will not benefit patients, the really good news is that the BAMI trial is well-designed, has clear and defined endpoints that are easy to assess (mortality and re-hospitalization) and is unlikely to be damaging to patients since they are receiving their own cells. Moreover, the trial at its conclusion will have developed several protocols that will be useful to the wider community considering future cell therapies. These include standardized methods for bone marrow cell collection and preparation for autologous transplantation into the heart.

Most importantly, the trial is very large (3000 patients) and statistically well-powered meaning that it should really put the question as to whether there is any benefit to the test. A few years from now, we should have a good sense of whether there is something interesting happening and maybe then scientists might invest some energy into figuring out how and why it might work.

David Kent holds a PhD in Genetics (UBC) and a BSc in Genetics and English (UWO) and is currently a CIHR postdoctoral fellow at the University of Cambridge, UK. He studies normal and malignant stem cell biology and currently sits on the executive for the Canadian Association of Postdoctoral Scholars. He also maintains his own blog for early career researchers at University Affairs, called the Black Hole (http://www.universityaffairs.ca/the-black-hole/).

View post:
Will bone marrow stem cells help heart attack patients ...

To Read More: Will bone marrow stem cells help heart attack patients …
categoriaBone Marrow Stem Cells commentoComments Off on Will bone marrow stem cells help heart attack patients … | dataMay 8th, 2014
Read All

Questions and Answers

By Sykes24Tracey

FAITH Stem Cell Research and Human Cloning by: FR. GAMMY TULABING I would like to share with you this article from the United States Conference of Catholic Bishops.

Questions and Answers

What is a stem cell?

A stem cell is a relatively unspecia-lized cell that, when it divides, can do two things: make another cell like itself, or make any of a number of cells with more specialized functions. For example, just one kind of stem cell in our blood can make new red blood cells, or white blood cells, or other kindsdepending on what the body needs. These cells are like the stem of a plant that spreads out in different directions as it grows.

Is the Catholic Church opposed to all stem cell research?

Not at all. Most stem cell research uses cells obtained from adult tissue, umbilical cord blood, and other sources that pose no moral problem. Useful stem cells have been found in bone marrow, blood, muscle, fat, nerves, and even in the pulp of baby teeth. Some of these cells are already being used to treat people with a wide variety of diseases.

Why is the Church opposed to stem cell research using the embryo?

Because harvesting these stem cells kills the living human embryo. The church opposes the direct destruction of innocent human life for any purpose, including research.

If some human embryos will remain in frozen storage and ultimately be discarded anyway, why is it wrong to try to get some good out of them?

In the end, we will all die anyway, but that gives no one a right to kill us. In any case, these embryos will not die because they are inherently unable to survive, but because others are choosing to hand them over for destructive research instead of letting them implant in their mothers womb. One wrong choice does not justify an additional wrong choice to kill them for research, much less a choice to make tax payers support such destruction. The idea of experimenting on human beings because they may die anyway also poses a grave threat to convicted prisoners, terminally ill patients, and others.

Original post:
Questions and Answers

To Read More: Questions and Answers
categoriaBone Marrow Stem Cells commentoComments Off on Questions and Answers | dataMay 5th, 2014
Read All

Stem Therapy May Improve Survival of Heart Patients

By Sykes24Tracey

A new review of previous scientific studies has concluded that stem cell therapy may help reduce the number of deaths in heart patients.

The Cochrane Heart Review Group analyzed data from studies involving just over 1,200 patients in 23 randomized, controlled trials.

The group's report on the potential benefits of stem cell heart repair was published online on April 29 in The Cochrane Library. The Cochrane Reviews are systematic assessments of evidence-based research into human health care and health policy.

There were fewer deaths among heart patients receiving stem cell therapy in addition to standard treatment, compared to patients who were treated with traditional therapies alone or with a placebo. Stem cells are primitive master cells that, under the right conditions, can turn into any cell in the body.

The therapy also reduced the chances that patients, with improved heart function, had to be readmitted to the hospital.

The review noted that stem cell therapy could possibly reduce the number of deaths after one year, but the results of larger clinical trials are needed.

The stem cells are taken from a patients own bone marrow and injected into the hearts of patients with ischemic heart disease and congestive heart failure, repairing damaged cardiac tissue.

Dr. Enca Martin-Rendon, author of the review in Britain, said, This is encouraging evidence that stem cell therapy has benefits for heart disease patients. However, Martin-Rendon noted it is difficult to come to any concrete conclusions until larger clinical trials are carried out.

Link:
Stem Therapy May Improve Survival of Heart Patients

To Read More: Stem Therapy May Improve Survival of Heart Patients
categoriaUncategorized commentoComments Off on Stem Therapy May Improve Survival of Heart Patients | dataMay 3rd, 2014
Read All

Heart Muscles Repaired After Heart Attack Using Human Embryonic Stem Cells

By Sykes24Tracey

Image Caption: This image shows an implanted graft of cardiac cells derived from human stem cells (green) meshed and beat with primates' heart cells (red). Credit: Murry Lab/University of Washington

April Flowers for redOrbit.com Your Universe Online

When a heart attack occurs, the oxygen-rich blood that normally flows through is interrupted by the blockage in an artery. The longer that blood flow is restricted or cut off, the more tissue and muscle in the area dies or is scarred. The eventual result can be heart failure, especially if one heart attack is followed by another.

In 2013, Harvard Health Publications released a report taking a look at the state of stem cell research into the problem of regenerating heart tissue, and the results were mixed.

A new study from the University of Washington, however, reveals improvement in those results. The findings, published online in Nature, demonstrate that damaged heart muscles in monkeys have been restored by the use of heart cells created from human embryonic stem cells. The exciting implication, according to the research team, is that their approach should also be feasible in humans.

Before this study, it was not known if it is possible to produce sufficient numbers of these cells and successfully use them to remuscularize damaged hearts in a large animal whose heart size and physiology is similar to that of the human heart, said Dr. Charles Murry, UW professor of pathology and bioengineering and director of the UW Center for Cardiovascular Biology, in a recent statement.

Murray, who collaborated with Dr. Michael Laflamme and other colleagues at the UW Institute for Stem Cell & Regenerative Medicine, predicts clinical trials with humans within the next four years.

[ Watch the Video: Regenerating Heart Muscle Damage With Stem Cell Therapy ]

For the study, the researchers induced controlled myocardial infarctions, a type of heart attack, in anesthetized pigtail macaques, by blocking the coronary artery for 90 minutes. This is the accepted practice for studying myocardial infarction in primates.

Coronary artery disease is the primary culprit in myocardial infarctions in humans. The infarcted heart muscle, damaged by a lack of oxygen, does not grow back, leaving the heart less able to pump blood. This often leads to heart failure, the leading cause of cardiovascular death. Researchers hope to use new heart cells created from stem cells in order to restore normal function to the failing heart.

Read the original here:
Heart Muscles Repaired After Heart Attack Using Human Embryonic Stem Cells

To Read More: Heart Muscles Repaired After Heart Attack Using Human Embryonic Stem Cells
categoriaCardiac Stem Cells commentoComments Off on Heart Muscles Repaired After Heart Attack Using Human Embryonic Stem Cells | dataMay 2nd, 2014
Read All

Stem cell breakthrough in treating heart attacks

By Sykes24Tracey

An implanted graft of cardiac cells derived from human stem cells (green) meshed with a monkey's own heart cells (red). Picture: Murry Lab/University of Washington/PA

Stem cell heart repair treatments could be tested on human patients within four years following a ground-breaking study of monkeys.

Scientists successfully restored damaged cardiac muscle in macaque monkeys suffering the after-effects of experimentally induced heart attacks, paving the way to clinical trials.

Researchers injected 1bn immature heart muscle cells derived from human embryonic stem cells into each animals heart.

Over several weeks, the new cells developed, assembled into muscle fibres, and began to beat in correct time. On average, 40% of the damaged heart tissue was regenerated.

It is the first time stem cell therapy for damage caused by heart attacks has been shown to work in a primate.

Lead scientist Prof Charles Murry, director of the Centre for Cardiovascular Biology at the University of Washington in Seattle, said: Before this study, it was not known if it is possible to produce sufficient numbers of these cells and successfully use them to remuscularise damaged hearts in a large animal whose heart size and physiology is similar to that of the human heart.

He expects the treatment to be ready for clinical trials in human patients within four years.

Heart attack symptoms were triggered in the monkeys by blocking the coronary artery the main artery supplying the heart with blood for 90 minutes.

In humans, the reduced blood flow caused by narrowing of the arteries has a similar effect. Lack of blood flow to the heart damages the heart muscle by depriving it of oxygen.

View original post here:
Stem cell breakthrough in treating heart attacks

To Read More: Stem cell breakthrough in treating heart attacks
categoriaCardiac Stem Cells commentoComments Off on Stem cell breakthrough in treating heart attacks | dataMay 2nd, 2014
Read All

Stem cells could be used to treat heart disease

By Sykes24Tracey

Stem cells could be used to treat heart disease

6:30am Friday 2nd May 2014 in News

STEM cells taken from bone marrow could be used to treat heart disease by injecting them into damaged tissue, early results show.

Stem cells are cells in the body which have not yet specialised and can become any type.

Oxford University scientists hailed the encouraging evidence in results of 26 small clinical trails involving 1,255 people.

A year or more after treatment, just three per cent of people had died, compared with 15 per cent of people who had not had the procedure.

Hospital readmissions stood at only two in 100 for those testing out the new treatment.

Dr Enca Martin-Rendon, who carried out the study with the Cochrane Heart Review Group, said larger studies would be carried out to get more conclusive evidence.

Go here to see the original:
Stem cells could be used to treat heart disease

To Read More: Stem cells could be used to treat heart disease
categoriaBone Marrow Stem Cells commentoComments Off on Stem cells could be used to treat heart disease | dataMay 2nd, 2014
Read All

'Provocative' Research Turns Skin Cells Into Sperm

By Sykes24Tracey

hide captionNew research could be promising for infertile men. Scientists were able to make immature sperm cells from skin cells. Their next challenge is to make that sperm viable.

New research could be promising for infertile men. Scientists were able to make immature sperm cells from skin cells. Their next challenge is to make that sperm viable.

Scientists reported Thursday they had figured out a way to make primitive human sperm out of skin cells, an advance that could someday help infertile men have children.

"I probably get 200 emails a year from people who are infertile, and very often the heading on the emails is: Can you help me?" says Renee Reijo Pera of Montana State University, who led the research when she was at Stanford University.

In a paper published in the journal Cell Reports, Pera and her colleagues describe what they did. They took skin cells from infertile men and manipulated them in the laboratory to become induced pluripotent stem cells, which are very similar to human embryonic stem cells. That means they have the ability to become virtually any cell in the body.

They then inserted the cells into the testes of mice, where they became very immature human sperm cells, the researchers report.

"It's much easier than we actually expected," Pera told Shots.

Other researchers caution that there's still much more research that is needed to prove these cells would actually become healthy sperm that could make a baby. But they said the report was intriguing.

"It's one step closer to being able to make sperm in a petri dish," says George Daley, a stem-cell researcher at Harvard. "So I think that's very provocative."

But others worry the techniques could be misused.

Link:
'Provocative' Research Turns Skin Cells Into Sperm

To Read More: 'Provocative' Research Turns Skin Cells Into Sperm
categoriaSkin Stem Cells commentoComments Off on 'Provocative' Research Turns Skin Cells Into Sperm | dataMay 2nd, 2014
Read All

Sperm precursors made from stem cells of infertile men

By Sykes24Tracey

PUBLIC RELEASE DATE:

1-May-2014

Contact: Mary Beth O'Leary moleary@cell.com 617-397-2802 Cell Press

Researchers reporting in the Cell Press journal Cell Reports on May 1st have successfully coaxed stem cells made from the skin cells of infertile men into producing sperm cell precursors. These induced pluripotent stem cells (iPSCs) produced sperm precursors following transplantation into the testes of mice.

The findings help to explain a genetic cause of male infertility and offer a window into basic sperm biology. The approach also holds considerable potential for clinical application, the researchers say.

"Our results are the first to offer an experimental model to study sperm development," said Renee Reijo Pera of the Institute for Stem Cell Biology & Regenerative Medicine and Montana State University. "Therefore, there is potential for applications to cell-based therapies in the clinic, for example, for the generation of higher quality and numbers of sperm in a dish.

"It might even be possible to transplant stem-cell-derived germ cells directly into the testes of men with problems producing sperm," she added. However, getting to that point will require considerable study to ensure the safety and practicality.

Infertility affects 10% to 15% of couples. Moreover, as the researchers note, genetic causes of infertility are surprisingly prevalent among men, most commonly due to the spontaneous loss of key genes on the Y sex chromosome. But the causes at the molecular level have not been well understood.

Reijo Pera said her primary motivation is to understand the fundamental decision early in development that enables the production of sperm cell precursors and ultimately sperm. One way to do that is to study cells lacking genes that are required for sperm production.

The researchers looked to infertile but otherwise normal men with deletions encompassing three Y chromosome azoospermia factor (AZF) regions, which are associated with the production of few or no sperm. They found that iPSCs derived from AZF-deleted cells were compromised in their ability to form sperm in a dish. But when those cells were transplanted into the seminiferous tubules of mice, they produced germ-cell-like cells (though significantly fewer than iPSCs derived from people without the AZF deletion do).

See original here:
Sperm precursors made from stem cells of infertile men

To Read More: Sperm precursors made from stem cells of infertile men
categoriaUncategorized commentoComments Off on Sperm precursors made from stem cells of infertile men | dataMay 2nd, 2014
Read All

Bone Marrow Recipients Get Rare Chance to Meet Their "Genetic Twins" at City of Hope

By Sykes24Tracey

Released: 4/28/2014 3:00 PM EDT Source Newsroom: City of Hope Contact Information

Available for logged-in reporters only

Newswise DUARTE, Calif. Bone marrow transplants offer a second chance for people with life-threatening blood cancers and other hematologic malignancies. But many recipients, though overwhelmed with curiosity and the need to express their gratitude, can only dream of meeting the strangers who saved their lives. City of Hope is about to make that dream come true for two patients.

At City of Hopes annual Bone Marrow Transplantation Reunion on May 9, two grateful patients will meet the strangers, each hailing from different countries, who gave them back their futures.

Shes a world away, and weve never met, but were in a way genetic twins, said George Winston, the impressionistic, genre-defying musician with more than 20 instrumental albums under his belt. Winston received a lifesaving transplant from a young German woman two years ago, and cant wait to get to know her. Its amazing how they can locate a donor. I cant wait to meet her and just thank her from the bottom of my heart.

The meetings are the public focal point of City of Hopes annual Celebration of Life. Other meetings, and reunions, will take place throughout the event, attended by more than 6,500 bone marrow, stem cell and cord blood transplant recipients, their families and donors. All will celebrate second chances, scientific breakthroughs and transplant anniversaries.

Each survivor wears a button proudly proclaiming the years since his or her transplant. For some, its only a year. For others, a few decades. They celebrate their own recoveries, and the medical advances that have allowed this fellowship of survivors to grow from just a single patient 38 years ago at the first reunion, to thousands.

City of Hope helped pioneer bone marrow transplantation nearly four decades ago and is now a leader in bone marrow, stem cell and cord blood transplant, preparing to formally launch its Hematologic Cancers Institute. City of Hope has the only transplant program in the nation to achieve nine consecutive reporting years of over performance in one-year overall patient survival, according to the most recent data from the Center for International Blood and Marrow Transplant Research, which tracks all such transplants performed in the U.S.

The reunion is a motivation that leaves us in awe of the many patients weve been able to help, but also humbled and focused on the patients currently in our care and those who will count on us in the future, said Stephen J. Forman, M.D., Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation. We dont have any results so good that they cannot be improved. Were always focused on how we can do this better. Were never satisfied.

Two patients will be highlighted as part of the reunion, and will meet their donors for the first time ever.

See the rest here:
Bone Marrow Recipients Get Rare Chance to Meet Their "Genetic Twins" at City of Hope

To Read More: Bone Marrow Recipients Get Rare Chance to Meet Their "Genetic Twins" at City of Hope
categoriaBone Marrow Stem Cells commentoComments Off on Bone Marrow Recipients Get Rare Chance to Meet Their "Genetic Twins" at City of Hope | dataApril 29th, 2014
Read All

Diabetic Woman's Cells Are Turned Into Embryonic Stem Cells

By Sykes24Tracey

Scientists have used cloning technology to make stem cells from a woman with Type 1 diabetes that are genetically matched to her and to her disease.

They hope to someday use such cells as tailor-made transplants to treat or potentially even cure the disease, which affects millions and which now has few treatment options other than careful diet and regular use of insulin.

Its the second report his month of success in using cloning technology to make human embryonic stem cells the cells that eventually create a complete human being and that scientists hope to harness to treat diseases ranging from diabetes to Parkinsons and injuries that cause paralysis or organ damage.

I think this is going to become reality, Dr. Dieter Egli of the New York Stem Cell Foundation, whose report is published in the journal Nature on Monday, told reporters. It may be a bit in the future but it is going to happen.

The technique they use is called somatic cell nuclear transfer the same method used to make Dolly, the sheep who was the first mammal to be cloned, in 1996. Scientists remove the nucleus from a normal cell, clear the nucleus from a human egg cell, then inject the nucleus from the skin cell into the egg.

I think this is going to become reality."

Various chemical or electrical tricks can be used to start the egg growing as if it had been fertilized by sperm. In this case, they used DNA from a woman with Type 1 diabetes, and they said they used an improved method to trick the egg into developing.

It got to whats called a blastocyst a ball of cells that has not yet begun to differentiate into the different types of cells and tissues in the body, such as nerve cells, blood cells and bone cells. They removed individual cells and used various chemical baths to direct them to form into the desired cell type the beta cells in the pancreas that make insulin and that are destroyed in diabetes. These cells carry the patients own unique DNA, including whatever genetic mistakes led to her diabetes.

These stem cells could therefore be used to generate cells for therapeutic cell replacement, they wrote in their report.

Scientists have cloned sheep, pigs, mice and monkeys, but its been far harder to clone human beings. Its partly because of the controversy few people advocate cloning humans for the purpose of making babies, and many people object to destroying a human embryo, even one that only ever existed in a lab dish.

Excerpt from:
Diabetic Woman's Cells Are Turned Into Embryonic Stem Cells

To Read More: Diabetic Woman's Cells Are Turned Into Embryonic Stem Cells
categoriaSkin Stem Cells commentoComments Off on Diabetic Woman's Cells Are Turned Into Embryonic Stem Cells | dataApril 29th, 2014
Read All

First disease-specific human embryonic stem cell line by nuclear transfer

By Sykes24Tracey

Using somatic cell nuclear transfer, a team of scientists led by Dr. Dieter Egli at the New York Stem Cell Foundation (NYSCF) Research Institute and Dr. Mark Sauer at Columbia University Medical Center has created the first disease-specific embryonic stem cell line with two sets of chromosomes.

As reported today in Nature, the scientists derived embryonic stem cells by adding the nuclei of adult skin cells to unfertilized donor oocytes using a process called somatic cell nuclear transfer (SCNT). Embryonic stem cells were created from one adult donor with type 1 diabetes and a healthy control. In 2011, the team reported creating the first embryonic cell line from human skin using nuclear transfer when they made stem cells and insulin-producing beta cells from patients with type 1 diabetes. However, those stem cells were triploid, meaning they had three sets of chromosomes, and therefore could not be used for new therapies.

The investigators overcame the final hurdle in making personalized stem cells that can be used to develop personalized cell therapies. They demonstrated the ability to make a patient-specific embryonic stem cell line that has two sets of chromosomes (a diploid state), the normal number in human cells. Reports from 2013 showed the ability to reprogram fetal fibroblasts using SCNT; however, this latest work demonstrates the first successful derivation by SCNT of diploid pluripotent stem cells from adult and neonatal somatic cells.

"From the start, the goal of this work has been to make patient-specific stem cells from an adult human subject with type 1 diabetes that can give rise to the cells lost in the disease," said Dr. Egli, the NYSCF scientist who led the research and conducted many of the experiments. "By reprograming cells to a pluripotent state and making beta cells, we are now one step closer to being able to treat diabetic patients with their own insulin-producing cells."

"I am thrilled to say we have accomplished our goal of creating patient-specific stem cells from diabetic patients using somatic cell nuclear transfer," said Susan L. Solomon, CEO and co-founder of NYSCF. "I became involved with medical research when my son was diagnosed with type 1 diabetes, and seeing today's results gives me hope that we will one day have a cure for this debilitating disease. The NYSCF laboratory is one of the few places in the world that pursues all types of stem cell research. Even though many people questioned the necessity of continuing our SCNT work, we felt it was critical to advance all types of stem-cell research in pursuit of cures. We don't have a favorite cell type, and we don't yet know what kind of cell is going to be best for putting back into patients to treat their disease."

The research is the culmination of an effort begun in 2006 to make patient-specific embryonic stem cell lines from patients with type 1 diabetes. Ms. Solomon opened NYSCF's privately funded laboratory on March 1, 2006, to facilitate the creation of type 1 diabetes patient-specific embryonic stem cells using SCNT. Initially, the stem cell experiments were done at Harvard and the skin biopsies from type 1 diabetic patients at Columbia; however, isolation of the cell nuclei from these skin biopsies could not be conducted in the federally funded laboratories at Columbia, necessitating a safe-haven laboratory to complete the research. NYSCF initially established its lab, now the largest independent stem cell laboratory in the nation, to serve as the site for this research.

In 2008, all of the research was moved to the NYSCF laboratory when the Harvard scientists determined they could no longer move forward, as restrictions in Massachusetts prevented their obtaining oocytes. Dr. Egli left Harvard University and joined NYSCF; at the same time, NYSCF forged a collaboration with Dr. Sauer who designed a unique egg-donor program that allowed the scientists to obtain oocytes for the research.

"This project is a great example of how enormous strides can be achieved when investigators in basic science and clinical medicine collaborate. I feel fortunate to have been able to participate in this important project," said Dr. Sauer. Dr. Sauer is vice chair of the Department of Obstetrics and Gynecology, professor of obstetrics and gynecology, and chief of reproductive endocrinology at Columbia University Medical Center and program director of assisted reproduction at the Center for Women's Reproductive Care.

Patients with type 1 diabetes lack insulin-producing beta cells, resulting in insulin deficiency and high blood-sugar levels. Therefore, producing beta cells from stem cells for transplantation holds promise as a treatment and potential cure for type 1 diabetes. Because the stem cells are made using a patient's own skin cells, the beta cells for replacement therapy would be autologous, or from the patient, matching the patient's DNA.

Generating autologous beta cells using SCNT is only the first step in developing a complete cell replacement therapy for type 1 diabetes. In type 1 diabetes, the body's immune system attacks its own beta cells; therefore, further work is underway at NYSCF, Columbia, and other institutions to develop strategies to protect existing and therapeutic beta cells from attack by the immune system, as well as to prevent such attack.

More:
First disease-specific human embryonic stem cell line by nuclear transfer

To Read More: First disease-specific human embryonic stem cell line by nuclear transfer
categoriaIPS Cell Therapy commentoComments Off on First disease-specific human embryonic stem cell line by nuclear transfer | dataApril 29th, 2014
Read All

Stem cell therapy | irish stem cells – Video

By Sykes24Tracey


Stem cell therapy | irish stem cells
http://www.arthritistreatmentcenter.com So what #39;s going on in Ireland when it comes to arthritis... coming up next... First signs of arthritis cure seen by I...

By: Nathan Wei

Read the original here:
Stem cell therapy | irish stem cells - Video

To Read More: Stem cell therapy | irish stem cells – Video
categoriaUncategorized commentoComments Off on Stem cell therapy | irish stem cells – Video | dataApril 29th, 2014
Read All

First Human Skin Sample 'Grown' In Lab, Could Artificial Epidermis End Animal Testing?

By Sykes24Tracey

A team of researchers from Kings College London and the San Francisco Veteran Medical Center announced on Thursday that they were able to grow an epidermis that had the same permeability as real human skin, by using pluripotent stem cells. Pluripotent stem cells are cultured from adult cells and can develop into any type of cell or tissue.

Researchers say the artificial human skin offers a cost-effective alternative technique for testing drugs and cosmetics.

Our new method can be used to grow much greater quantities of lab-grown human epidermal equivalents, and thus could be scaled up for commercial testing of drugs and cosmetics, Dusko Ilic, leader of the team at King's College London, said in a statement. We can use this model to study how the skin barrier develops normally, how the barrier is impaired in different diseases and how we can stimulate its repair and recovery.

The new study, published in the journalStem Cell Reports,details how researchers triggered pluripotent stem cells to generate an unlimited supply of pure keratinocytes -- the primary cell type of the epidermis. In a high-humidity environment, scientists grew three-dimensional epidermal samples.

The samples engineered in the lab showed no significant differences in structure or function compared with real human skin samples, according to researchers.

Since the 1920s, the U.S. and other industrialized nations have used animals to test the safety and effectiveness of various drugs and vaccines. In the cosmetic industry, nonhuman test subjects, including rabbits, monkeys, rats and dogs, undergo skin and eye irritation tests in which chemicals are rubbed onto sections of shaved skin or dripped into the eyes of restrained test subjects. Some are even forced to swallow large amounts of certain chemicals to determine what constitutes a lethal dose.

While the use of animal testing, particularly Draize Testing, in which test substances are administered to the eye or skin has declined in recent years in the U.S. and Europe, it is still legal in 80 percent of countries. According to the Humane Society, in China alone, an estimated 300,000 animal die each year in cosmetic tests.

Human epidermal equivalents representing different types of skin could also be grown, depending on the source of the stem cells used, Ilic said. [They can] be tailored to study a range of skin conditions and sensitivities in different populations.

The rest is here:
First Human Skin Sample 'Grown' In Lab, Could Artificial Epidermis End Animal Testing?

To Read More: First Human Skin Sample 'Grown' In Lab, Could Artificial Epidermis End Animal Testing?
categoriaSkin Stem Cells commentoComments Off on First Human Skin Sample 'Grown' In Lab, Could Artificial Epidermis End Animal Testing? | dataApril 27th, 2014
Read All

Former Ennis Coach Sam Harrell is Back Thanks to Stem Cell Therapy – Video

By Sykes24Tracey


Former Ennis Coach Sam Harrell is Back Thanks to Stem Cell Therapy
Sam Harrell won three state football championships at Ennis High School, but perhaps the toughest battle he has faced has been off the field with MS. Jeff Po...

By: Jeff Power TV Productions JPTV

The rest is here:
Former Ennis Coach Sam Harrell is Back Thanks to Stem Cell Therapy - Video

To Read More: Former Ennis Coach Sam Harrell is Back Thanks to Stem Cell Therapy – Video
categoriaUncategorized commentoComments Off on Former Ennis Coach Sam Harrell is Back Thanks to Stem Cell Therapy – Video | dataApril 27th, 2014
Read All

Research aims to improve bone disease treatment

By Sykes24Tracey

Research team at York University aims to improve bone disease treatment

12:45pm Friday 25th April 2014 in News By Barry Nelson, Health Editor

RESEARCHERS are aiming to develop new therapies for osteoarthritis by rejuvenating old stem cells to repair cartilage damage.

A research team at York University have been awarded 190,158 from the medical research charity Arthritis Research UK to carry out a three-year study to investigate how rejuvenated cells from older people with osteoarthritis can be used to repair worn or damaged cartilage, reducing chronic pain.

There is currently no treatment to prevent the progression of osteoarthritis, and people with severe disease often need total joint replacement surgery.

A patients own bone marrow stem cells are a valuable source of potential treatment as they can generate joint tissue that wont be rejected when re-implanted. However, as people grow older the number of stem cells decreases and those that remain are less able to grow and repair tissue.

Dr Paul Genever, lead researcher, who heads up the Arthritis Research UK Tissue Engineering Centre at the University of York said: A way to reset stem cells to an earlier time point, termed rejuvenation, has recently been discovered, allowing more effective tissue repair.

This project will firstly compare rejuvenated and non-rejuvenated stem cells to see if the process improves cartilage repair, and secondly, investigate whether it is possible to develop new drugs which are able to rejuvenate stem cells.

In the UK, more than 8m people, have sought treatment from their GP for the condition, which causes pain and stiffness in the joints due to cartilage at the ends of bones wearing away.

Professor Alan Silman, medical director at charity Arthritis Research UK, said: This is pioneering research, which has the potential to help reduce pain and disability and improving quality of life of those living with osteoarthritis.

Follow this link:
Research aims to improve bone disease treatment

To Read More: Research aims to improve bone disease treatment
categoriaBone Marrow Stem Cells commentoComments Off on Research aims to improve bone disease treatment | dataApril 25th, 2014
Read All

Stem Cell Therapy | bone marrow concentrate for osteoarthritis – Video

By Sykes24Tracey


Stem Cell Therapy | bone marrow concentrate for osteoarthritis
http://www.arthritistreatmentcenter.com In the next video I #39;ll report on another study showing the effectiveness of stem cells in the treatment of osteoarthritis... New Study Shows Positive...

By: Nathan Wei

Link:
Stem Cell Therapy | bone marrow concentrate for osteoarthritis - Video

To Read More: Stem Cell Therapy | bone marrow concentrate for osteoarthritis – Video
categoriaUncategorized commentoComments Off on Stem Cell Therapy | bone marrow concentrate for osteoarthritis – Video | dataApril 24th, 2014
Read All

Irish cell therapy firm in E6m research

By Sykes24Tracey

Tuesday, April 22 11:57:06

Orbsen Therapeutics, a spin-out from NUI Galway's Regenerative Medicine Institute (REMEDI), is to partner with the University of Birmingham in a E6 million EU FP7 funded MERLIN project to fight liver disease.

The EU FP7-funded project known by the acronym "MERLIN" (MEsynchymal stem cells to Reduce Liver INflammation) is led by Professor Phil Newsome, Clinical Director of the Birmingham University Stem Cell Centre. MERLIN will advance Orbsen's proprietary cell therapy to a Phase 2a clinical trial in patients with inflammatory liver disease. This MERLIN project will evaluate the Orbsen cell therapy in 4 different research laboratories across Europe and the project will culminate in a Phase 2a clinical trial of the therapy in the crippling inflammatory liver disease, Primary Sclerosing Cholangitis.

This is Orbsen's fourth success in attracting FP7 funding (the EU's Seventh Framework Programme for Research), making them one of Ireland's most successful private companies in this funding programme and now connects Orbsen to 23 global collaborators. Other successful cell therapy projects for Orbsen include PURSTEM (completed), REDDSTAR (ongoing) and DeCIDE (ongoing).

Orbsen Therapeutics Ltd. is a privately-held company founded in 2006 as a spin-out from Ireland's Regenerative Medicine Institute (REMEDI) in NUI Galway. As part of the PurStem EU FP7 program, Orbsen developed proprietary technologies that enable the prospective purification of highly defined and therapeutic (stromal) cells from several human tissues, including bone marrow, adipose tissue and umbilical cord.

Orbsen's CEO Brian Molloy said, "Orbsen has secured substantial amounts of research funding in the last 18 months which will further validate our product and bring us through to a "first in man" clinical trial in 2015/16. Our model has always focused on putting the 'science first' and we have successfully used that approach to develop a technology that could potentially position us and indeed Ireland at the leading edge of European Cell Therapy development."

Mr Molloy continued, "As a spin-out from the NUI Galway based REMEDI Institute we have focused the majority of our collaborations with an Irish research team. Our success in the MERLIN project now demonstrates that we are capable of playing a key role in collaborations led by researchers across Europe."

The total research budget for the MERLIN project is close to E6 Million of which E1 Million will go directly to Orbsen Therapeutics over the 4-year period of the project.

Link:
Irish cell therapy firm in E6m research

To Read More: Irish cell therapy firm in E6m research
categoriaUncategorized commentoComments Off on Irish cell therapy firm in E6m research | dataApril 23rd, 2014
Read All

Stem – Cell Transplant Vs. Bone – Marrow Transplant | eHow

By Sykes24Tracey

Browse Articles & Videos By Category

Jacquelyn Jeanty

Jacquelyn Jeanty has worked as a freelance writer since 2008. Her work appears at various websites. Her specialty areas include health, home and garden, Christianity and personal development. Jeanty holds a Bachelor of Arts in psychology from Purdue University.

Since 1968, bone-marrow transplant procedures have been used to treat diseases such as leukemia, lymphomas and immune-deficiency disorders. By comparison, stem-cell transplants procedures are a fairly new development within the medical-science world. As a result, the potential uses and risks involved with stem-cell procedures are as of yet not fully known.

Transplant procedures are intended to replace defective or damaged tissues and cells with cells that are able to replace damaged tissue and restore normal function within the body. The use of bone-marrow material versus stem cell material is actually referring to two sides of the same coin, as bone marrow is a type of stem cell derived from the cells inside the bone. Stem cells, in general, can be taken from a number of sources, some of which include the umbilical cord, fetal material, the placenta, somatic cells, embryonic materials, as well as bone marrow material. The type of transplant procedure used will depend on the type of treatment needed and the area of the body affected.

Stem-cell research is a developing field in which stem cells are used to cure diseases, engineer gene-types and clone animals and humans. What makes stem cells so promising is their ability to evolve into a variety of different tissue forms. When used to treat diseased tissues, stem cells may provide a permanent cure as healthy new cells reproduce and replace defective cell organisms. This type of transplant may someday provide a way to treat cancer formations inside the body. Bone marrow stem cells are being used to replace unhealthy bone marrow in people who suffer from blood-borne diseases such as leukemia.

As with any type of surgical procedure, certain risks are involved when undergoing a stem-cell transplant. Frequent testing and possible hospitalizations may be necessary after the procedure is done. Individuals who receive donor stem cells may experience what's called the "graft-versus-host disease." This condition occurs when the patient's immune system reacts to the transplanting of donor stem cells. Symptoms of graft-versus-host disease include vomiting, diarrhea, skin rashes and abdominal pain. Organ damage, blood vessel damage and secondary cancers are other possible complications that can arise.

Bone-marrow material is made up of the soft tissue contained inside the bones. This material is responsible for producing and storing the body's blood cells. Bone marrow can be extracted from the breast bone, the hips, the spine, the ribs and the skull. Transplant materials can be used to replace unhealthy bone material for individuals who've undergone radiation or chemotherapy treatments. Individuals who suffer from a genetic disease such as Hurler's syndrome or adrenoleukodystrophy can also benefit from receiving a healthy supply of bone-marrow material.

The risks involved with bone marrow transplants vary depending on how healthy a person is, the type of transplant being done and how compatible a donor's material is. Individuals who've undergone chemotherapy or radiation treatments may experience complications because of the weakened state that the body is in. As bone-marrow material can come from the patient or from a donor, compatibility risks are more of a concern when donor materials are used. Possible complications from a transplant include anemia, infection, internal bleeding or internal-organ damage.

There are different types of bone marrow transplants, including an allogeneic and an autologous transplant. In allogeneic bone marrow transplants, stem cells...

See the original post here:
Stem - Cell Transplant Vs. Bone - Marrow Transplant | eHow

To Read More: Stem – Cell Transplant Vs. Bone – Marrow Transplant | eHow
categoriaBone Marrow Stem Cells commentoComments Off on Stem – Cell Transplant Vs. Bone – Marrow Transplant | eHow | dataApril 22nd, 2014
Read All

Top Phoenix Foot and Ankle Specialist, Valley Foot Surgeons, Now Offering Stem Cell Procedures for Healing Diabetic …

By Sykes24Tracey

Phoenix, Arizona (PRWEB) April 21, 2014

The top foot and ankle specialists in Arizona at Valley Foot Surgeons are now offering stem cell treatments for diabetic wounds. The treatments may propel these difficult wounds to heal in a much shorter time frame than they would without regenerative medicine therapy. The stem cell doctor is a four-time Phoenix Magazine Top Doc Winner; call (480) 994-5977 for more information and scheduling.

With up to a third of individuals suffering from diabetes (or pre-diabetes), wounds and ulcers are becoming more common all the time in the foot and ankle area. Due to the immunocompromised state of diabetics, it can be extremely difficult for the human body to naturally heal these wounds. Sometimes, they persist for years, become infected, and may lead to an eventual need for an amputation.

At Valley Foot Surgeons, Phoenix Top Doc Richard Jacoby is now offering stem cell treatments for diabetic wounds. These treatments are performed as an outpatient and involve subcutaneous injections of amniotic derived stem cell material around the wound.

The procedure offers several benefits in addition to a hefty concentration of stem cells. The material is immunologically privileged and does not cause a rejection reaction. It is processed from an FDA regulated lab.

The amniotic derived stem cells assists with the creation of new blood vessels to help heal the wounds and also contains a significant amount of growth factors. The stem cell material also has antimicrobial properties, helping avoid infection.

Along with the stem cell procedures, Valley Foot Surgeons offers laser treatment simultaneously which further helps with the healing process. With approximately 100 stem cell procedures performed so far for diabetic wounds, the outcomes have been nothing short of incredible.

Wounds have been healing, and much faster than with conventional methods. For more information and treatment with the top foot and ankle stem cell doctor in Phoenix and Scottsdale, call (480) 420-3499.

Read the original:
Top Phoenix Foot and Ankle Specialist, Valley Foot Surgeons, Now Offering Stem Cell Procedures for Healing Diabetic ...

To Read More: Top Phoenix Foot and Ankle Specialist, Valley Foot Surgeons, Now Offering Stem Cell Procedures for Healing Diabetic …
categoriaUncategorized commentoComments Off on Top Phoenix Foot and Ankle Specialist, Valley Foot Surgeons, Now Offering Stem Cell Procedures for Healing Diabetic … | dataApril 21st, 2014
Read All

Scientists create stem cells from adults

By Sykes24Tracey

Scientists have moved a step closer to the goal of creating stem cells perfectly matched to a patient's DNA in order to treat diseases, they announced on Thursday, creating patient-specific cell lines out of the skin cells of two adult men.

The advance, described online in the journal Cell Stem Cell, is the first time researchers have achieved "therapeutic cloning" of adults. Technically called somatic-cell nuclear transfer, therapeutic cloning means producing embryonic cells genetically identical to a donor, usually for the purpose of using those cells to treat disease.

But nuclear transfer is also the first step in reproductive cloning, or producing a genetic duplicate of someone - a technique that has sparked controversy since the 1997 announcement that it was used to create Dolly, the clone of a ewe. In 2005, the United Nations called on countries to ban it, and the United States prohibits the use of federal funds for either reproductive or therapeutic cloning.

The new study was funded by a foundation and the South Korean government.

If confirmed by other labs, it could prove significant because many illnesses that might one day be treated with stem cells, such as heart failure and vision loss, primarily affect adults. Patient-specific stem cells would have to be created from older cells, not infant or fetal ones. That now looks possible, though far from easy: Out of 39 tries, the scientists created stem cells only once for each donor.

Outside experts had different views of the study, which was led by Young Gie Chung of the Research Institute for Stem Cell Research at CHA Health Systems in Los Angeles.

Stem cell biologist George Daley of the Harvard Stem Cell Institute called it "an incremental advance" and "not earth-shattering."

Reproductive biologist Shoukhrat Mitalipov of Oregon Health and Science University, who developed the technique the CHA team adapted, was more positive. "The advance here is showing that (nuclear transfer) looks like it will work with people of all ages," he said in an interview.

A year ago, Mitalipov led the team that used nuclear transfer of fetal and infant DNA to produce stem cells, the first time that had been accomplished in humans of any age.

ELECTRIC JOLT

See the article here:
Scientists create stem cells from adults

To Read More: Scientists create stem cells from adults
categoriaSkin Stem Cells commentoComments Off on Scientists create stem cells from adults | dataApril 18th, 2014
Read All

Page 21«..10..20212223..3040..»


Copyright :: 2024